{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"75"}],"units":"Participants"}],"description":"Transformation-free survival is defined as one of the following:\n\n1. Myelofibrosis (MF) as evidenced by bone marrow biopsy, or\n2. Acute leukemia as evidenced by bone marrow blast counts of at least 20%, or peripheral blast counts of at least 20% lasting at least 2 weeks.\n3. Death due to any cause during treatment period","groups":[{"description":"Ruxolitinib at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid","id":"OG000","title":"Ruxolitinib"},{"description":"Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib","id":"OG001","title":"Best Available Therapy (BAT)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Analysis Set (FAS) included all participants to whom study treatment was assigned by randomization and had valid measurements for the outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 260 (ruxolitinib arm) and Week 80 (BAT arm)","title":"Number of Participants With Transformation Free Survival Events","type":"SECONDARY","unitOfMeasure":"Participants"}